Celgene Corp (CELG) Tops Q2 EPS by 1c; Raises Guidance
Get Alerts CELG Hot Sheet
Financial Fact:
Acquisition related (gains) charges and restructuring, net: 25M
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Celgene Corp (NASDAQ: CELG) reported Q2 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.85 billion.
Celgene Corp sees FY2014 EPS of $3.60-$3.65, versus prior guidance of $3.50-$3.60 and the consensus of $3.67. Celgene Corp sees FY2014 revenue of $7.6 billion, versus prior guidance of $7.54 billion and the consensus of $7.5 billion.
“Strong second quarter operating and financial results demonstrate the significant momentum of our portfolio and support raising our 2014 guidance,” said Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. “We look forward to multiple milestones in the second half of the year, including the expansion of OTEZLA® into psoriasis and the further advancement of our pipeline.”
For earnings history and earnings-related data on Celgene Corp (CELG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Augmedix, Inc. (AUGX) Tops Q4 EPS by 1c
- Motus GI Holdings (MOTS) Tops Q4 EPS by 130c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!